vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Oscar Health, Inc. (OSCR). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $9.0M, roughly 54.4× Oscar Health, Inc.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -3933.2%, a 3923.1% gap on every dollar of revenue. On growth, Oscar Health, Inc. posted the faster year-over-year revenue change (86.3% vs 44.7%). Oscar Health, Inc. produced more free cash flow last quarter ($662.8M vs $-68.7M). Over the past eight quarters, Oscar Health, Inc.'s revenue compounded faster (26.1% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Oscar Health, Inc. is an American for-profit health insurance company, founded in 2012 by Joshua Kushner, Kevin Nazemi and Mario Schlosser, and is headquartered in New York City. The company focuses on the health insurance industry through telemedicine, healthcare focused technological interfaces, and transparent claims pricing systems which would make it easier for patients to navigate.

CLOV vs OSCR — Head-to-Head

Bigger by revenue
CLOV
CLOV
54.4× larger
CLOV
$487.7M
$9.0M
OSCR
Growing faster (revenue YoY)
OSCR
OSCR
+41.6% gap
OSCR
86.3%
44.7%
CLOV
Higher net margin
CLOV
CLOV
3923.1% more per $
CLOV
-10.1%
-3933.2%
OSCR
More free cash flow
OSCR
OSCR
$731.6M more FCF
OSCR
$662.8M
$-68.7M
CLOV
Faster 2-yr revenue CAGR
OSCR
OSCR
Annualised
OSCR
26.1%
18.6%
CLOV

Income Statement — Q4 2025 vs Q4 2025

Metric
CLOV
CLOV
OSCR
OSCR
Revenue
$487.7M
$9.0M
Net Profit
$-49.3M
$-352.6M
Gross Margin
Operating Margin
-10.1%
-3722.8%
Net Margin
-10.1%
-3933.2%
Revenue YoY
44.7%
86.3%
Net Profit YoY
-123.2%
-129.6%
EPS (diluted)
$-1.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
OSCR
OSCR
Q4 25
$487.7M
$9.0M
Q3 25
$496.6M
$8.8M
Q2 25
$477.6M
$6.5M
Q1 25
$462.3M
$4.3M
Q4 24
$337.0M
$4.8M
Q3 24
$331.0M
$4.9M
Q2 24
$356.3M
$5.2M
Q1 24
$346.9M
$5.6M
Net Profit
CLOV
CLOV
OSCR
OSCR
Q4 25
$-49.3M
$-352.6M
Q3 25
$-24.4M
$-137.4M
Q2 25
$-10.6M
$-228.4M
Q1 25
$-1.3M
$275.3M
Q4 24
$-22.1M
$-153.5M
Q3 24
$-9.2M
$-54.6M
Q2 24
$7.4M
$56.2M
Q1 24
$-19.2M
$177.4M
Gross Margin
CLOV
CLOV
OSCR
OSCR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
CLOV
CLOV
OSCR
OSCR
Q4 25
-10.1%
-3722.8%
Q3 25
-4.9%
-1468.6%
Q2 25
-2.2%
-3547.5%
Q1 25
-0.3%
Q4 24
-6.4%
-3070.1%
Q3 24
-2.7%
-987.4%
Q2 24
2.0%
Q1 24
-6.5%
Net Margin
CLOV
CLOV
OSCR
OSCR
Q4 25
-10.1%
-3933.2%
Q3 25
-4.9%
-1561.8%
Q2 25
-2.2%
-3514.9%
Q1 25
-0.3%
6357.3%
Q4 24
-6.6%
-3190.9%
Q3 24
-2.8%
-1114.4%
Q2 24
2.1%
1074.5%
Q1 24
-5.5%
3148.2%
EPS (diluted)
CLOV
CLOV
OSCR
OSCR
Q4 25
$-1.19
Q3 25
$-0.53
Q2 25
$-0.89
Q1 25
$0.92
Q4 24
$-0.50
Q3 24
$-0.22
Q2 24
$0.20
Q1 24
$0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
OSCR
OSCR
Cash + ST InvestmentsLiquidity on hand
$78.3M
$2.8B
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$977.6M
Total Assets
$541.0M
$6.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
OSCR
OSCR
Q4 25
$78.3M
$2.8B
Q3 25
$2.1B
Q2 25
$2.6B
Q1 25
$2.2B
Q4 24
$194.5M
$2.2B
Q3 24
$288.0M
$1.2B
Q2 24
$254.8M
$2.3B
Q1 24
$208.3M
$2.2B
Stockholders' Equity
CLOV
CLOV
OSCR
OSCR
Q4 25
$308.7M
$977.6M
Q3 25
$340.9M
$1.0B
Q2 25
$344.2M
$1.2B
Q1 25
$336.1M
$1.3B
Q4 24
$341.1M
$1.0B
Q3 24
$342.2M
$1.2B
Q2 24
$324.9M
$1.1B
Q1 24
$292.5M
$1.0B
Total Assets
CLOV
CLOV
OSCR
OSCR
Q4 25
$541.0M
$6.3B
Q3 25
$559.7M
$5.7B
Q2 25
$575.0M
$6.4B
Q1 25
$583.7M
$5.8B
Q4 24
$580.7M
$4.8B
Q3 24
$653.0M
$4.5B
Q2 24
$674.2M
$5.0B
Q1 24
$671.8M
$4.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
OSCR
OSCR
Operating Cash FlowLast quarter
$-68.2M
$671.9M
Free Cash FlowOCF − Capex
$-68.7M
$662.8M
FCF MarginFCF / Revenue
-14.1%
7393.7%
Capex IntensityCapex / Revenue
0.1%
101.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.0M
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
OSCR
OSCR
Q4 25
$-68.2M
$671.9M
Q3 25
$12.1M
$-964.7M
Q2 25
$5.4M
$509.1M
Q1 25
$-16.3M
$878.5M
Q4 24
$-85.8M
$346.8M
Q3 24
$50.0M
$-500.1M
Q2 24
$44.8M
$497.2M
Q1 24
$25.9M
$634.4M
Free Cash Flow
CLOV
CLOV
OSCR
OSCR
Q4 25
$-68.7M
$662.8M
Q3 25
$11.4M
$-973.7M
Q2 25
$4.8M
$499.8M
Q1 25
$-16.5M
$869.5M
Q4 24
$-86.1M
$340.0M
Q3 24
$49.6M
$-507.7M
Q2 24
$44.4M
$489.6M
Q1 24
$25.5M
$628.4M
FCF Margin
CLOV
CLOV
OSCR
OSCR
Q4 25
-14.1%
7393.7%
Q3 25
2.3%
-11063.1%
Q2 25
1.0%
7692.6%
Q1 25
-3.6%
20081.2%
Q4 24
-25.6%
7065.7%
Q3 24
15.0%
-10363.5%
Q2 24
12.5%
9359.4%
Q1 24
7.3%
11153.9%
Capex Intensity
CLOV
CLOV
OSCR
OSCR
Q4 25
0.1%
101.1%
Q3 25
0.1%
102.3%
Q2 25
0.1%
142.8%
Q1 25
0.0%
208.5%
Q4 24
0.1%
141.7%
Q3 24
0.1%
154.4%
Q2 24
0.1%
144.6%
Q1 24
0.1%
105.6%
Cash Conversion
CLOV
CLOV
OSCR
OSCR
Q4 25
Q3 25
Q2 25
Q1 25
3.19×
Q4 24
Q3 24
Q2 24
6.04×
8.85×
Q1 24
3.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons